Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Statistical Methods in Medical Research
|
February 21, 2008
Surrogate endpoint validation: statistical elegance versus clinical relevance
Em Green, G Yothers, Daniel J Sargent
Journal of the National Cancer Institute
|
December 21, 2000
HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15
S Paik, J Bryant, E Tan-Chiu, et al.
Journal of the National Cancer Institute. Monographs
|
January 5, 2002
Adjuvant therapy for very young women with breast cancer: need for tailored treatments
A Goldhirsch, R D Gelber, G Yothers, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 25, 2011
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803
D Sargent, Q Shi, G Yothers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 18, 2015
Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials
D G Haller, M J O'Connell, T H Cartwright, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 21, 2015
Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†
L A Renfro, A Grothey, D Kerr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 4, 2019
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies
J Taieb, Q Shi, L Pederson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 23, 2020
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database
M E Salem, J Yin, R M Goldberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 24, 2023
Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials
J Taieb, F A Sinicrope, L Pederson, et al.
ESMO Open
|
March 5, 2025
Impact of tumor and node stages on the efficacy of adjuvant oxaliplatin-based chemotherapy in stage III colon cancer patients: an ACCENT pooled analysis
R Cohen, M Raeisi, B Chibaudel, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Statistical Methods in Medical Research
|
February 21, 2008
Surrogate endpoint validation: statistical elegance versus clinical relevance
Em Green, G Yothers, Daniel J Sargent
Journal of the National Cancer Institute
|
December 21, 2000
HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15
S Paik, J Bryant, E Tan-Chiu, et al.
Journal of the National Cancer Institute. Monographs
|
January 5, 2002
Adjuvant therapy for very young women with breast cancer: need for tailored treatments
A Goldhirsch, R D Gelber, G Yothers, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 25, 2011
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803
D Sargent, Q Shi, G Yothers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 18, 2015
Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials
D G Haller, M J O'Connell, T H Cartwright, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 21, 2015
Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†
L A Renfro, A Grothey, D Kerr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 4, 2019
Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies
J Taieb, Q Shi, L Pederson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 23, 2020
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database
M E Salem, J Yin, R M Goldberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 24, 2023
Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials
J Taieb, F A Sinicrope, L Pederson, et al.
ESMO Open
|
March 5, 2025
Impact of tumor and node stages on the efficacy of adjuvant oxaliplatin-based chemotherapy in stage III colon cancer patients: an ACCENT pooled analysis
R Cohen, M Raeisi, B Chibaudel, et al.
Page
of 2